Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGN OTCMKTS:CLPBY NYSE:EW NYSE:SNN NYSE:ZBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGNAlign Technology$163.38+5.3%$174.54$122.00▼$208.30$11.70B1.71.16 million shs1.52 million shsCLPBYColoplast A/S$6.45+2.5%$6.63$6.10▼$10.03$14.54B0.15585,345 shs236,318 shsEWEdwards Lifesciences$82.85+0.8%$81.48$72.30▼$87.89$47.70B0.874.78 million shs4.03 million shsSNNSmith & Nephew SNATS$30.98+0.4%$32.07$28.23▼$38.79$13.23B0.571.01 million shs1.16 million shsZBHZimmer Biomet$85.29-0.9%$89.27$79.12▼$108.29$16.50B0.482.32 million shs2.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGNAlign Technology-2.28%-6.41%-18.37%-18.69%-16.06%CLPBYColoplast A/S-2.18%-2.18%-10.14%-17.67%-34.71%EWEdwards Lifesciences-0.31%+3.07%+1.38%+4.01%+5.27%SNNSmith & Nephew SNATS+1.68%+2.60%-10.19%-15.00%+5.96%ZBHZimmer Biomet+1.22%+3.21%-9.14%-12.31%-10.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGNAlign Technology$163.38+5.3%$174.54$122.00▼$208.30$11.70B1.71.16 million shs1.52 million shsCLPBYColoplast A/S$6.45+2.5%$6.63$6.10▼$10.03$14.54B0.15585,345 shs236,318 shsEWEdwards Lifesciences$82.85+0.8%$81.48$72.30▼$87.89$47.70B0.874.78 million shs4.03 million shsSNNSmith & Nephew SNATS$30.98+0.4%$32.07$28.23▼$38.79$13.23B0.571.01 million shs1.16 million shsZBHZimmer Biomet$85.29-0.9%$89.27$79.12▼$108.29$16.50B0.482.32 million shs2.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGNAlign Technology-2.28%-6.41%-18.37%-18.69%-16.06%CLPBYColoplast A/S-2.18%-2.18%-10.14%-17.67%-34.71%EWEdwards Lifesciences-0.31%+3.07%+1.38%+4.01%+5.27%SNNSmith & Nephew SNATS+1.68%+2.60%-10.19%-15.00%+5.96%ZBHZimmer Biomet+1.22%+3.21%-9.14%-12.31%-10.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGNAlign Technology 2.57Moderate Buy$205.8525.99% UpsideCLPBYColoplast A/S 1.50ReduceN/AN/AEWEdwards Lifesciences 2.79Moderate Buy$95.6515.46% UpsideSNNSmith & Nephew SNATS 2.40Hold$30.93-0.16% DownsideZBHZimmer Biomet 2.26Hold$102.8020.54% UpsideCurrent Analyst Ratings BreakdownLatest ALGN, CLPBY, EW, ZBH, and SNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026SNNSmith & Nephew SNATS Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.855/11/2026SNNSmith & Nephew SNATS Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$32.00 ➝ $30.004/30/2026ALGNAlign Technology EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$200.00 ➝ $220.004/30/2026ALGNAlign Technology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$225.00 ➝ $230.004/29/2026ZBHZimmer Biomet Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$83.004/29/2026ZBHZimmer Biomet Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$92.004/29/2026ZBHZimmer Biomet CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$98.00 ➝ $95.004/29/2026ZBHZimmer Biomet BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderweight$100.00 ➝ $94.004/29/2026ZBHZimmer Biomet JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$100.00 ➝ $95.004/29/2026ZBHZimmer Biomet Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$120.00 ➝ $105.004/29/2026ZBHZimmer Biomet Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$98.00 ➝ $90.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGNAlign Technology$4.03B2.90$12.21 per share13.38$57.94 per share2.82CLPBYColoplast A/S$4.13B3.52$0.36 per share17.93$1.06 per share6.08EWEdwards Lifesciences$6.30B7.57$2.87 per share28.89$17.94 per share4.62SNNSmith & Nephew SNATS$6.16B2.15$3.50 per share8.84$12.45 per share2.49ZBHZimmer Biomet$8.41B1.96$13.76 per share6.20$65.55 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGNAlign Technology$410.35M$5.9627.4115.661.6310.50%15.82%10.17%7/29/2026 (Estimated)CLPBYColoplast A/S$538.49M$0.1446.0715.002.037.46%31.96%10.20%N/AEWEdwards Lifesciences$1.07B$1.8844.0724.732.0717.39%15.19%11.71%7/23/2026 (Estimated)SNNSmith & Nephew SNATS$625MN/AN/A12.340.99N/AN/AN/A8/4/2026 (Estimated)ZBHZimmer Biomet$705.20M$3.8522.159.511.979.05%13.24%7.28%8/6/2026 (Estimated)Latest ALGN, CLPBY, EW, ZBH, and SNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q2 2026CLPBYColoplast A/S$0.09$0.10+$0.01-$0.07$1.11 billion$1.11 billion4/29/2026Q1 2026ALGNAlign Technology$2.26$2.58+$0.32$1.57$1.02 billion$1.04 billion4/28/2026Q1 2026ZBHZimmer Biomet$1.86$2.09+$0.23$1.22$2.07 billion$2.09 billion4/23/2026Q1 2026EWEdwards Lifesciences$0.7280$0.78+$0.0520$0.66$1.60 billion$1.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGNAlign TechnologyN/AN/AN/AN/AN/ACLPBYColoplast A/S$0.081.24%N/A57.14%N/AEWEdwards LifesciencesN/AN/AN/AN/AN/ASNNSmith & Nephew SNATS$0.933.00%N/AN/AN/AZBHZimmer Biomet$0.961.13%N/A24.94%N/ALatest ALGN, CLPBY, EW, ZBH, and SNN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2026SNNSmith & Nephew SNATS$0.48203.04%3/27/20263/27/20265/27/20262/23/2026ZBHZimmer Biometquarterly$0.241.06%3/31/20263/31/20264/30/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGNAlign TechnologyN/A1.391.28CLPBYColoplast A/S1.501.300.81EWEdwards Lifesciences0.064.423.63SNNSmith & Nephew SNATS0.602.571.25ZBHZimmer Biomet0.501.730.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGNAlign Technology88.43%CLPBYColoplast A/SN/AEWEdwards Lifesciences79.46%SNNSmith & Nephew SNATS25.64%ZBHZimmer Biomet88.89%Insider OwnershipCompanyInsider OwnershipALGNAlign Technology0.75%CLPBYColoplast A/SN/AEWEdwards Lifesciences0.31%SNNSmith & Nephew SNATS1.00%ZBHZimmer Biomet1.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGNAlign Technology20,29071.62 million71.08 millionOptionableCLPBYColoplast A/S17,1562.25 billionN/ANot OptionableEWEdwards Lifesciences16,000575.80 million574.02 millionOptionableSNNSmith & Nephew SNATS16,988426.99 million422.72 millionOptionableZBHZimmer Biomet17,000193.46 million190.99 millionOptionableALGN, CLPBY, EW, ZBH, and SNN HeadlinesRecent News About These CompaniesZimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of "Hold" from AnalystsMay 20 at 4:32 AM | marketbeat.comGabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBHMay 20 at 3:36 AM | marketbeat.comZimmer Biomet Holdings, Inc. $ZBH Shares Sold by Independent Advisor AllianceMay 19 at 4:49 AM | marketbeat.comHere's Why Zimmer Biomet (ZBH) is a Strong Value StockMay 18 at 10:40 AM | zacks.comABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?May 18 at 10:16 AM | zacks.comEubel Brady & Suttman Asset Management Inc. Decreases Position in Zimmer Biomet Holdings, Inc. $ZBHMay 17 at 6:50 AM | marketbeat.comHills Bank & Trust Co Sells 14,826 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 17 at 5:51 AM | marketbeat.comWhat are Wall Street analysts' target price for Zimmer Biomet stock?May 15, 2026 | msn.comZimmer Biomet (ZBH) Valuation Check After Announcing Expanded US$1b Share Repurchase PlanMay 15, 2026 | finance.yahoo.comZimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Thrivent Financial for LutheransMay 15, 2026 | marketbeat.comPacer Advisors Inc. Has $62.74 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBHMay 14, 2026 | marketbeat.comZimmer Biomet increases planned share repurchase to up to $1B by end of 2026May 13, 2026 | massdevice.comZimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comWhy Zimmer Biomet (ZBH) stock is up todayMay 13, 2026 | msn.comZimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year EndMay 12, 2026 | prnewswire.comKLCM Advisors Inc. Buys 58,427 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 12, 2026 | marketbeat.comZimmer Biomet (NYSE:ZBH) Reaches New 12-Month Low - Here's WhyMay 11, 2026 | marketbeat.comInvestors Can Find Comfort In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings QualityMay 11, 2026 | finance.yahoo.comBryn Mawr Trust Advisors LLC Sells 25,448 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 10, 2026 | marketbeat.comWhy Zimmer Biomet Is Stirring NYSE Composite Buzz?May 9, 2026 | kalkinemedia.comKSequoia Financial Advisors LLC Sells 16,194 Shares of Zimmer Biomet Holdings, Inc. $ZBHMay 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026Roblox Stock Slides to New Low as Safety Changes Weigh on OutlookBy Jennifer Ryan Woods | May 3, 2026Verizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 20263 European Bank Stocks Nearing New 52-Week HighsBy Dan Schmidt | April 27, 2026ALGN, CLPBY, EW, ZBH, and SNN Company DescriptionsAlign Technology NASDAQ:ALGN$163.38 +8.22 (+5.30%) Closing price 04:00 PM EasternExtended Trading$164.95 +1.57 (+0.96%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.Coloplast A/S OTCMKTS:CLPBY$6.45 +0.16 (+2.54%) As of 03:59 PM EasternColoplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.Edwards Lifesciences NYSE:EW$82.85 +0.69 (+0.84%) Closing price 03:59 PM EasternExtended Trading$82.46 -0.39 (-0.47%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Smith & Nephew SNATS NYSE:SNN$30.98 +0.14 (+0.44%) Closing price 03:58 PM EasternExtended Trading$31.00 +0.03 (+0.09%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.Zimmer Biomet NYSE:ZBH$85.29 -0.79 (-0.92%) Closing price 03:59 PM EasternExtended Trading$84.42 -0.87 (-1.02%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
